<SEC-DOCUMENT>0000899140-20-000256.txt : 20200423
<SEC-HEADER>0000899140-20-000256.hdr.sgml : 20200423
<ACCEPTANCE-DATETIME>20200423170029
ACCESSION NUMBER:		0000899140-20-000256
CONFORMED SUBMISSION TYPE:	SC 13D
PUBLIC DOCUMENT COUNT:		1
FILED AS OF DATE:		20200423
DATE AS OF CHANGE:		20200423

SUBJECT COMPANY:	

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Entasis Therapeutics Holdings Inc.
		CENTRAL INDEX KEY:			0001724344
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				824592913
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		SC 13D
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	005-90651
		FILM NUMBER:		20811725

	BUSINESS ADDRESS:	
		STREET 1:		35 GATEHOUSE DRIVE
		CITY:			WALTHAM
		STATE:			MA
		ZIP:			02451
		BUSINESS PHONE:		(781) 810-0120

	MAIL ADDRESS:	
		STREET 1:		35 GATEHOUSE DRIVE
		CITY:			WALTHAM
		STATE:			MA
		ZIP:			02451

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Entasis Therapeutics Ltd
		DATE OF NAME CHANGE:	20171204

FILED BY:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Innoviva, Inc.
		CENTRAL INDEX KEY:			0001080014
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				943265960
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		SC 13D

	BUSINESS ADDRESS:	
		STREET 1:		2000 SIERRA POINT PARKWAY
		STREET 2:		SUITE 500
		CITY:			BRISBANE
		STATE:			CA
		ZIP:			94005
		BUSINESS PHONE:		6502389600

	MAIL ADDRESS:	
		STREET 1:		2000 SIERRA POINT PARKWAY
		STREET 2:		SUITE 500
		CITY:			BRISBANE
		STATE:			CA
		ZIP:			94005

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	THERAVANCE INC
		DATE OF NAME CHANGE:	20020207

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ADVANCED MEDICINE INC
		DATE OF NAME CHANGE:	20000302
</SEC-HEADER>
<DOCUMENT>
<TYPE>SC 13D
<SEQUENCE>1
<FILENAME>e34301036a.htm
<DESCRIPTION>SCHEDULE 13D
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Willkie Farr Gallagher
         Document created using EDGARfilings PROfile 6.4.0.0
         Copyright 1995 - 2020 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman', Times, serif; font-size: 12pt; text-align: left; color: #000000;">
  <div>
    <div><br>
    </div>
    <div style="text-align: center; margin-right: 166.6pt; margin-left: 166.9pt; margin-top: 4.45pt; font-size: 10pt; font-weight: bold;">UNITED STATES</div>
    <div style="text-align: center; margin-right: 166.6pt; margin-left: 167pt; margin-top: 0.5pt; font-size: 10pt; font-weight: bold;">SECURITIES AND EXCHANGE COMMISSION</div>
    <div style="text-align: center; margin-right: 166.45pt; margin-left: 167pt; margin-top: 2.05pt; font-size: 10pt; font-weight: bold;">Washington, D.C.&#160; 20549</div>
    <div><br>
    </div>
    <div><br>
    </div>
    <div style="margin-top: 0.5pt;"><br>
    </div>
    <div style="text-align: center; margin-right: 166.6pt; margin-left: 166.95pt; font-size: 14pt; font-weight: bold;">SCHEDULE 13D</div>
    <div style="text-align: center; margin-right: 178.95pt; margin-left: 179.45pt; margin-top: 1.35pt; font-size: 10pt; font-weight: bold;">Under the Securities Exchange Act of 1934 (Amendment No.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;)*</div>
    <div><br>
    </div>
    <div style="text-align: center; font-size: 14pt; font-weight: bold;">ENTASIS THERAPEUTICS HOLDINGS INC.</div>
    <div style="margin-top: 0.1pt;">
      <hr noshade="noshade" align="center" style="height: 2px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;"></div>
    <div style="text-align: center; margin-right: 166.6pt; margin-left: 166.9pt; margin-top: 1.15pt; font-size: 10pt;">(Name of Issuer)</div>
    <div style="margin-top: 1.15pt;"><br>
    </div>
    <div style="text-align: center; font-size: 10pt; font-weight: bold;">Common Stock, $0.001 par value</div>
    <div style="margin-top: 0.1pt;">
      <hr noshade="noshade" align="center" style="height: 2px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;"></div>
    <div style="text-align: center; margin-right: 166.55pt; margin-left: 167pt; margin-top: 1.15pt; font-size: 10pt;">(Title of Class of Securities)</div>
    <div style="margin-top: 1.15pt;"><br>
    </div>
    <div style="text-align: center; font-size: 10pt; font-weight: bold;">293614 103</div>
    <div style="margin-top: 0.1pt;">
      <hr noshade="noshade" align="center" style="height: 2px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;"></div>
    <div style="text-align: center; margin-right: 166.6pt; margin-left: 166.9pt; margin-top: 1.15pt; font-size: 10pt;">(CUSIP Number)</div>
    <div style="margin-top: 1.15pt;"><br>
    </div>
    <div style="text-align: center; font-size: 10pt; font-weight: bold;">Geoffrey Hulme</div>
    <div style="text-align: center; font-size: 10pt; font-weight: bold;">Interim Principal Executive Officer</div>
    <div style="text-align: center; font-size: 10pt; font-weight: bold;">Innoviva, Inc.</div>
    <div style="text-align: center; font-size: 10pt; font-weight: bold;">1350 Old Bayshore Highway Suite 400</div>
    <div style="text-align: center; font-size: 10pt; font-weight: bold;">Burlingame, CA</div>
    <div style="text-align: center; font-size: 10pt; font-weight: bold;">877-202-1097</div>
    <div style="margin-top: 0.1pt;">
      <hr noshade="noshade" align="center" style="height: 2px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;"></div>
    <div style="margin: 1.15pt 0px 0px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; text-align: center;">(Name, Address and Telephone Number of Person Authorized to </div>
    <div style="margin: 1.15pt 0px 0px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; text-align: center;">Receive Notices and Communications)</div>
    <div style="margin-top: 1.15pt;"><br>
    </div>
    <div style="text-align: center; font-size: 10pt; font-weight: bold;">April 22, 2020</div>
    <div style="margin-top: 0.25pt;">
      <hr noshade="noshade" align="center" style="height: 2px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;"></div>
    <div style="margin: 1.15pt 0px 0px; font-family: 'Times New Roman',Times,serif; font-size: 10pt; text-align: center;">(Date of Event which Requires Filing of this Statement)</div>
    <div style="margin-top: 0.45pt;"><br>
    </div>
    <div style="text-align: justify; margin-right: 60.15pt; margin-left: 59pt; font-size: 10pt;">If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this
      schedule because of &#167;&#167;240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.&#160; &#9744;</div>
    <div style="margin-top: 0.45pt;"><br>
    </div>
    <div style="text-align: justify; margin-right: 60.2pt; margin-left: 59pt; margin-top: 4.55pt; font-size: 10pt;"><font style="font-weight: bold;">Note</font>: Schedules filed in paper format shall include a signed original and five copies of the
      schedule, including all exhibits. See &#167;240.13d-7 for other parties to whom copies are to be sent.</div>
    <div><br>
    </div>
    <div style="text-align: justify; margin-right: 60.05pt; margin-left: 58.95pt; margin-top: 0.05pt; font-size: 10pt;"><font style="font-size: 8pt;">* </font>The remainder of this cover page shall be filled out for a reporting person&#8217;s initial filing on
      this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.</div>
    <div><br>
    </div>
    <div style="text-align: justify; margin-right: 60.15pt; margin-left: 58.95pt; margin-top: 0.05pt; font-size: 10pt;">The information required on the remainder of this cover page shall not be deemed to be &#8220;filed&#8221; for the purpose of Section 18 of the
      Securities Exchange Act of 1934 (&#8220;Act&#8221;) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).</div>
    <div><br>
    </div>
    <div style="margin-right: 117.45pt; margin-left: 86pt; margin-top: 5.75pt; font-size: 10pt; font-weight: bold;">Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently
      valid OMB control number.</div>
    <div style="margin-top: 0.1pt;"><br>
    </div>
    <div style="margin-left: 5pt; margin-top: 4.6pt; font-size: 10pt;">SEC 1746 (3-06)</div>
    <div><br>
    </div>
  </div>
  <div id="DSPFPageBreakArea" style="clear: both; margin-top: 12pt; margin-bottom: 12pt;">
    <div id="DSPFPageBreak" style="page-break-after: always;">
      <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
  </div>
  <!--PROfilePageNumberReset%Num%2%%%-->
  <div>
    <div>
      <div>
        <table cellspacing="0" cellpadding="3" border="0" style="font-family: 'Times New Roman', Times, serif; font-size: 12pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">

            <tr>
              <td style="width: 7.75%; vertical-align: middle;">&#160;</td>
              <td style="width: 1.55%; vertical-align: bottom;">&#160;</td>
              <td style="width: 7.74%; vertical-align: middle;">&#160;</td>
              <td style="width: 1.37%; vertical-align: bottom;">&#160;</td>
              <td style="width: 2.76%; vertical-align: middle;">&#160;</td>
              <td style="width: 1.37%; vertical-align: bottom;">&#160;</td>
              <td style="width: 77.48%; vertical-align: middle;">&#160;</td>
            </tr>
            <tr>
              <td style="width: 7.75%; vertical-align: top; border-left: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
                <div style="font-size: 10pt;">&#160;&#160;<font style="font-weight: bold;">1</font>&#160;</div>
              </td>
              <td style="width: 1.55%; vertical-align: bottom; border-left: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
                <div>&#160;</div>
              </td>
              <td style="width: 90.71%; vertical-align: top; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;" colspan="5">
                <div style="font-size: 10pt;">Names of Reporting Persons.<br>
                </div>
                <div style="font-size: 10pt;">I.R.S. Identification Nos. of above persons (entities only).<br>
                </div>
                <div>&#160;</div>
                <div style="margin-bottom: 1pt;">
                  <div style="font-size: 10pt;"><u>Innoviva, Inc.</u></div>
                </div>
                <div>&#160;</div>
              </td>
            </tr>
            <tr>
              <td style="width: 7.75%; vertical-align: top; border-left: #000000 2px solid; border-bottom: #000000 2px solid;">
                <div style="font-size: 10pt;">&#160;&#160;<font style="font-weight: bold;">2</font></div>
              </td>
              <td style="width: 1.55%; vertical-align: bottom; border-left: #000000 2px solid; border-bottom: #000000 2px solid;">
                <div style="font-size: 10pt;">&#160;</div>
              </td>
              <td style="width: 90.71%; vertical-align: top; border-right: #000000 2px solid; border-bottom: #000000 2px solid;" colspan="5">
                <div style="font-size: 10pt;">CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP</div>
                <div style="font-size: 10pt;">(a)&#160;&#160;<font style="font-family: 'Segoe UI Symbol', sans-serif;">&#9744;</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(b)&#160;&#160;<font style="font-family: 'Segoe UI Symbol', sans-serif;">&#9744;</font></div>
                <div style="margin-bottom: 1pt;">&#160;</div>
                <div>&#160;</div>
              </td>
            </tr>
            <tr>
              <td style="width: 7.75%; vertical-align: top; border-left: #000000 2px solid; border-bottom: #000000 2px solid;">
                <div style="font-size: 10pt;">&#160;&#160;<font style="font-weight: bold;">3</font></div>
              </td>
              <td style="width: 1.55%; vertical-align: bottom; border-left: #000000 2px solid; border-bottom: #000000 2px solid;">
                <div>&#160;</div>
              </td>
              <td style="width: 90.71%; vertical-align: top; border-right: #000000 2px solid; border-bottom: #000000 2px solid;" colspan="5">
                <div style="font-size: 10pt;">SEC USE ONLY</div>
                <div style="margin-bottom: 1pt;">&#160;</div>
                <div>&#160;</div>
              </td>
            </tr>
            <tr>
              <td style="width: 7.75%; vertical-align: top; border-left: #000000 2px solid; border-bottom: #000000 2px solid;">
                <div style="font-size: 10pt;">&#160;&#160;<font style="font-weight: bold;">4</font></div>
              </td>
              <td style="width: 1.55%; vertical-align: bottom; border-left: #000000 2px solid; border-bottom: #000000 2px solid;">
                <div>&#160;</div>
              </td>
              <td style="width: 90.71%; vertical-align: top; border-right: #000000 2px solid; border-bottom: #000000 2px solid;" colspan="5">
                <div style="font-size: 10pt;">SOURCE OF FUNDS</div>
                <div>&#160;</div>
                <div style="margin-bottom: 1pt; font-size: 10pt;">WC</div>
                <div>&#160;</div>
              </td>
            </tr>
            <tr>
              <td style="width: 7.75%; vertical-align: top; border-left: #000000 2px solid; border-bottom: #000000 2px solid;">
                <div style="font-size: 10pt;">&#160;&#160;<font style="font-weight: bold;">5</font></div>
              </td>
              <td style="width: 1.55%; vertical-align: bottom; border-left: #000000 2px solid; border-bottom: #000000 2px solid;">
                <div>&#160;</div>
              </td>
              <td style="width: 90.71%; vertical-align: top; border-right: #000000 2px solid; border-bottom: #000000 2px solid;" colspan="5">
                <div style="font-size: 10pt;">CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e)</div>
                <div>&#160;</div>
                <div style="margin-bottom: 1pt; font-family: 'Segoe UI Symbol',sans-serif; font-size: 10pt;">&#9744;</div>
                <div>&#160;</div>
              </td>
            </tr>
            <tr>
              <td style="width: 7.75%; vertical-align: top; border-left: #000000 2px solid; border-bottom: #000000 2px solid;">
                <div style="font-size: 10pt;">&#160;&#160;<font style="font-weight: bold;">6</font></div>
              </td>
              <td style="width: 1.55%; vertical-align: bottom; border-left: #000000 2px solid; border-bottom: #000000 2px solid;">
                <div>&#160;</div>
              </td>
              <td style="width: 90.71%; vertical-align: top; border-right: #000000 2px solid; border-bottom: #000000 2px solid;" colspan="5">
                <div style="font-size: 10pt;">CITIZENSHIP OR PLACE OF ORGANIZATION</div>
                <div>&#160;</div>
                <div style="margin-bottom: 1pt; font-size: 10pt;">Delaware</div>
                <div>&#160;</div>
              </td>
            </tr>
            <tr>
              <td style="width: 17.03%; vertical-align: middle; border-left: #000000 2px solid;" rowspan="4" colspan="3">
                <div style="text-align: center; font-size: 10pt;">NUMBER&#160;OF</div>
                <div style="text-align: center; font-size: 10pt;">SHARES</div>
                <div style="text-align: center; font-size: 10pt;">BENEFICIALLY</div>
                <div style="text-align: center; font-size: 10pt;">OWNED&#160;BY</div>
                <div style="text-align: center; font-size: 10pt;">EACH</div>
                <div style="text-align: center; font-size: 10pt;">REPORTING</div>
                <div style="text-align: center; font-size: 10pt;">PERSON</div>
                <div style="text-align: center; font-size: 10pt;">WITH</div>
                <div style="margin-bottom: 1pt; font-size: 10pt;">&#160;</div>
                <div>&#160;</div>
              </td>
              <td style="width: 1.37%; vertical-align: bottom; border-left: #000000 2px solid; border-bottom: #000000 2px solid;">
                <div>&#160;&#160;</div>
              </td>
              <td style="width: 2.76%; vertical-align: top; border-bottom: #000000 2px solid;">
                <div style="font-size: 10pt;">&#160;&#160;<font style="font-weight: bold;">7</font>&#160;</div>
              </td>
              <td style="width: 1.37%; vertical-align: bottom; border-left: #000000 2px solid; border-bottom: #000000 2px solid;">
                <div>&#160;&#160;</div>
              </td>
              <td style="width: 77.48%; vertical-align: top; border-right: #000000 2px solid; border-bottom: #000000 2px solid;">
                <div style="font-size: 10pt;">SOLE VOTING POWER</div>
                <div>&#160;</div>
                <div style="margin-bottom: 1pt;">
                  <div style="font-size: 10pt;">2,645,020<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(1)</sup></div>
                </div>
                <div>&#160;</div>
              </td>
            </tr>
            <tr>
              <td style="width: 1.55%; vertical-align: bottom; border-left: #000000 2px solid; border-bottom: #000000 2px solid;">
                <div>&#160;&#160;</div>
              </td>
              <td style="width: 7.74%; vertical-align: top; border-bottom: #000000 2px solid;">
                <div style="font-size: 10pt;">&#160;&#160;<font style="font-weight: bold;">8</font></div>
              </td>
              <td style="width: 1.37%; vertical-align: bottom; border-left: #000000 2px solid; border-bottom: #000000 2px solid;">
                <div>&#160;&#160;</div>
              </td>
              <td style="width: 2.76%; vertical-align: top; border-right: #000000 2px solid; border-bottom: #000000 2px solid;">
                <div style="font-size: 10pt;">SHARED VOTING POWER</div>
                <div>&#160;</div>
                <div style="margin-bottom: 1pt;">0<br>
                </div>
                <div>&#160;</div>
              </td>
            </tr>
            <tr>
              <td style="width: 1.55%; vertical-align: bottom; border-left: #000000 2px solid; border-bottom: #000000 2px solid;">
                <div>&#160;&#160;</div>
              </td>
              <td style="width: 7.74%; vertical-align: top; border-bottom: #000000 2px solid;">
                <div style="font-size: 10pt;">&#160;&#160;<font style="font-weight: bold;">9</font></div>
              </td>
              <td style="width: 1.37%; vertical-align: bottom; border-left: #000000 2px solid; border-bottom: #000000 2px solid;">
                <div>&#160;&#160;</div>
              </td>
              <td style="width: 2.76%; vertical-align: top; border-right: #000000 2px solid; border-bottom: #000000 2px solid;">
                <div style="font-size: 10pt;">SOLE DISPOSITIVE POWER</div>
                <div>&#160;</div>
                <div style="margin-bottom: 1pt; font-size: 10pt;">2,645,020<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(1)</sup><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;"></sup></div>
                <div>&#160;</div>
              </td>
            </tr>
            <tr>
              <td style="width: 1.55%; vertical-align: bottom; border-left: #000000 2px solid;">
                <div>&#160;&#160;</div>
              </td>
              <td style="width: 7.74%; vertical-align: top;">
                <div style="font-size: 10pt; font-weight: bold;">10</div>
              </td>
              <td style="width: 1.37%; vertical-align: bottom; border-left: #000000 2px solid;">
                <div>&#160;&#160;</div>
              </td>
              <td style="width: 2.76%; vertical-align: top; border-right: #000000 2px solid;">
                <div style="font-size: 10pt;">SHARED DISPOSITIVE POWER</div>
                <div>&#160;</div>
                <div style="margin-bottom: 1pt;"><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">0</sup></div>
                <div>&#160;</div>
              </td>
            </tr>
            <tr>
              <td style="width: 7.75%; vertical-align: top; border-left: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
                <div style="font-size: 10pt; font-weight: bold;">11</div>
              </td>
              <td style="width: 1.55%; vertical-align: bottom; border-left: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
                <div>&#160;</div>
              </td>
              <td style="width: 90.71%; vertical-align: top; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;" colspan="5">
                <div style="font-size: 10pt;">AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON</div>
                <div>&#160;</div>
                <div style="margin-bottom: 1pt;"><font style="font-size: 10pt;">2,645,020<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(1)</sup></font><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;"></sup></div>
                <div>&#160;</div>
              </td>
            </tr>
            <tr>
              <td style="width: 7.75%; vertical-align: top; border-left: #000000 2px solid; border-bottom: #000000 2px solid;">
                <div style="font-size: 10pt; font-weight: bold;">12</div>
              </td>
              <td style="width: 1.55%; vertical-align: bottom; border-left: #000000 2px solid; border-bottom: #000000 2px solid;">
                <div>&#160;</div>
              </td>
              <td style="width: 90.71%; vertical-align: top; border-right: #000000 2px solid; border-bottom: #000000 2px solid;" colspan="5">
                <div style="font-size: 10pt;">CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES</div>
                <div>&#160;</div>
                <div style="margin-bottom: 1pt; font-family: 'Segoe UI Symbol',sans-serif; font-size: 10pt;">&#9744;</div>
                <div>&#160;</div>
              </td>
            </tr>
            <tr>
              <td style="width: 7.75%; vertical-align: top; border-left: #000000 2px solid; border-bottom: #000000 2px solid;">
                <div style="font-size: 10pt; font-weight: bold;">13</div>
              </td>
              <td style="width: 1.55%; vertical-align: bottom; border-left: #000000 2px solid; border-bottom: #000000 2px solid;">
                <div>&#160;</div>
              </td>
              <td style="width: 90.71%; vertical-align: top; border-right: #000000 2px solid; border-bottom: #000000 2px solid;" colspan="5">
                <div style="font-size: 10pt;">PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)<br>
                </div>
                <div>&#160;</div>
                <div style="margin-bottom: 1pt;"><font style="font-size: 10pt;">19.996% <sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(1) (2)</sup></font><br>
                </div>
                <div>&#160;</div>
              </td>
            </tr>
            <tr>
              <td style="width: 7.75%; vertical-align: top; border-left: #000000 2px solid; border-bottom: #000000 2px solid;">
                <div style="font-size: 10pt; font-weight: bold;">14</div>
              </td>
              <td style="width: 1.55%; vertical-align: bottom; border-left: #000000 2px solid; border-bottom: #000000 2px solid;">
                <div>&#160;</div>
              </td>
              <td style="width: 90.71%; vertical-align: top; border-right: #000000 2px solid; border-bottom: #000000 2px solid;" colspan="5">
                <div style="font-size: 10pt;">TYPE OF REPORTING PERSON</div>
                <div>&#160;</div>
                <div style="margin-bottom: 1pt; font-size: 10pt;">CO</div>
                <div>&#160;</div>
              </td>
            </tr>

        </table>
      </div>
    </div>
    <div>
      <div><br>
      </div>
      <div>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 12pt; margin-top: 0.5pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z887ffe45f98b42799637a19356886e20">

            <tr>
              <td style="width: 36pt; vertical-align: top; align: right;">
                <div style="margin-left: 18pt; margin-top: 0.5pt; font-size: 10pt;">(1)</div>
              </td>
              <td style="width: auto; vertical-align: top;">
                <div style="margin-top: 0.5pt; font-size: 10pt;">See Item 5.</div>
              </td>
            </tr>

        </table>
      </div>
      <div>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 12pt; margin-top: 0.5pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zfcf653d942934a8f960ac803c336fc95">

            <tr>
              <td style="width: 36pt; vertical-align: top; align: right;">
                <div style="margin-left: 18pt; margin-top: 0.5pt; font-size: 10pt;">(2)</div>
              </td>
              <td style="width: auto; vertical-align: top;">
                <div style="margin-top: 0.5pt; font-size: 10pt;">Based on 13,231,716 shares of Common Stock outstanding as of April 22, 2020, as confirmed in writing by the Issuer, inclusive of the shares of Common Stock held by the Reporting Person and
                  shares of Common Stock issuable upon exercise of the Warrants held by the Reporting Person.</div>
              </td>
            </tr>

        </table>
      </div>
    </div>
  </div>
  <div id="DSPFPageBreakArea" style="clear: both; margin-top: 12pt; margin-bottom: 12pt;">
    <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-size: 10pt; font-weight: normal; font-style: normal;">2</font></div>
    <div id="DSPFPageBreak" style="page-break-after: always;">
      <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
  </div>
  <div><br>
    <div style="margin-left: 22.4pt; font-size: 10pt; font-weight: bold;">Item 1. Security and Issuer</div>
    <div style="margin-top: 0.4pt;"><br>
    </div>
    <div style="text-align: justify; text-indent: 36pt; margin-right: 23.65pt; margin-left: 22.4pt; margin-top: 0.05pt; font-size: 10pt;">This Statement of Beneficial Ownership on Schedule 13D (the &#8220;<font style="font-style: italic;">Schedule 13D</font>&#8221;)
      relates to 1,322,510 shares of common stock, $0.001 par value per share (&#8220;<font style="font-style: italic;">Common Stock</font>&#8221;) of Entasis Therapeutics Holdings Inc., a Delaware corporation (the &#8220;<font style="font-style: italic;">Issuer</font>&#8221;)
      and warrants to acquire an additional 1,322,510 shares of Common Stock of the Issuer, which are exercisable immediately and will have a five year term (&#8220;<font style="font-style: italic;">Warrants</font>&#8221;). The Issuer maintains its principal executive
      office at 35 Gatehouse Drive, Waltham, MA 02451.</div>
    <div style="margin-top: 0.05pt;"><br>
    </div>
    <div style="text-align: justify; text-indent: 36pt; margin-right: 23.65pt; margin-left: 22.4pt; margin-top: 0.05pt; font-size: 10pt;">The form of Warrant is attached as Exhibit 4.1 to the Form 8-K of the Issuer filed with the U.S. Securities and
      Exchange Commission on April 13, 2020 and is incorporated by reference in this Schedule 13D; any description herein of the Form of Warrant is qualified in its entirety by reference to the Form of Warrant so filed by the Issuer.</div>
    <div style="margin-top: 0.45pt;"><br>
    </div>
    <div style="margin-left: 22.4pt; font-size: 10pt; font-weight: bold;">Item 2. Identity and Background</div>
    <div style="margin-top: 0.4pt;"><br>
    </div>
    <div style="margin-left: 36pt; font-size: 10pt;">Innoviva, Inc. (the &#8220;<font style="font-style: italic;">Reporting Person</font>&#8221;) is a company with a portfolio of royalties that include respiratory assets, organized under the laws of the state of
      Delaware.</div>
    <div><br>
    </div>
    <div style="text-indent: 36pt; font-size: 10pt;">The address of the principal business office of the Reporting Person is 1350 Old Bayshore Highway Suite 400</div>
    <div style="margin-left: 36pt; font-size: 10pt;">Burlingame, CA.</div>
    <div><br>
    </div>
    <div style="margin-left: 36pt; color: #000000; font-size: 10pt;">The directors and executive officers of the Reporting Person are set forth on Schedule I, attached hereto. Schedule I sets forth the following information with respect to each such
      person:</div>
    <div style="color: #000000; font-size: 10pt;">&#160;</div>
    <div style="text-indent: 36pt; margin-left: 36pt; color: #000000; font-size: 10pt;">(i)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; name;</div>
    <div style="color: #000000; font-size: 10pt;">&#160;</div>
    <div style="text-indent: 36pt; margin-left: 36pt; color: #000000; font-size: 10pt;">(ii)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; business address;</div>
    <div style="color: #000000; font-size: 10pt;">&#160;</div>
    <div style="margin-left: 72pt; color: #000000; font-size: 10pt;">(iii)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; position with the Reporting Person and present principal occupation or employment and, for persons not employed by the Reporting Persons, the name, principal business and
      address of any corporation or other organization in which such employment is conducted; and</div>
    <div style="color: #000000; font-size: 10pt;">&#160;</div>
    <div style="text-indent: 36pt; margin-left: 36pt; color: #000000; font-size: 10pt;">(iv)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; citizenship.</div>
    <div style="margin-left: 36pt; font-size: 10pt;">&#160;</div>
    <div style="margin-left: 36pt; font-size: 10pt;">During the last five years, neither the Reporting Person nor any person named in Schedule I have been convicted in a criminal proceeding. During the last five years, neither the Reporting Person nor any
      person named in Schedule I have been a party to any other civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding was or is subject to a judgment, decree or final order enjoining future
      violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws.</div>
    <div style="margin-top: 0.25pt;"><br>
    </div>
    <div style="margin-left: 23.6pt; margin-top: 0.05pt; font-size: 10pt; font-weight: bold;">Item 3. Source and Amount of Funds or Other Consideration</div>
    <div style="margin-top: 0.4pt;"><br>
    </div>
    <div style="margin-left: 36pt;"><font style="font-size: 10pt;">The aggregate purchase price for the Common Stock and Warrants reported in this Schedule 13D was approximately $3.3 million. The Common Stock and Warrants reported in this Schedule 13D were
        acquired with funds provided from working capital of the Reporting Person</font>.</div>
    <div style="margin-top: 0.15pt;"><br>
    </div>
    <div style="margin-left: 23.55pt; margin-top: 0.05pt; font-size: 10pt; font-weight: bold;">Item 4. Purpose of Transaction</div>
    <div style="margin-top: 0.4pt;"><br>
    </div>
    <div style="margin-left: 36pt; font-size: 10pt;">The Reporting Person purchased the Common Stock and Warrants reported in this Schedule 13D for investment purposes pursuant to that certain Securities Purchase Agreement, dated as of April 12, 2020, by
      and between the Reporting Person and the Issuer (the &#8220;<font style="font-style: italic;">Purchase Agreement</font>&#8221;).&#160; Pursuant to the terms of the Purchase Agreement, in addition to the Common Stock and Warrants reported in this Schedule 13D, the
      Reporting Person may acquire an additional 12,677,490 shares of Common Stock and additional Warrants to purchase 12,677,490 shares of Common Stock of the Issuer, subject to satisfaction of certain conditions set forth in the Purchase Agreement,
      including that the Purchase Agreement and the transactions contemplated thereby having been approved by the stockholders of the Issuer as may be required by the applicable rules and regulations of <font style="color: #000000;">Nasdaq Stock Market
        LLC</font>.</div>
    <div><br>
    </div>
    <div style="margin-left: 36pt; font-size: 10pt;">The Purchase Agreement is attached as Exhibit 10.1 to the Form 8-K of the Issuer filed with the U.S. Securities and Exchange Commission (the &#8220;<font style="font-style: italic;">SEC</font>&#8221;) on April 13,
      2020 and is incorporated by reference in this Schedule 13D; any description herein of the Purchase Agreement is qualified in its entirety by reference to the Purchase Agreement so filed by the Issuer.</div>
    <div><br>
    </div>
    <div style="margin-left: 36pt; font-size: 10pt;">The Reporting Person may, from time to time and at any time, either alone or together with others: (i)&#160;acquire additional Common Stock and Warrants and/or other equity, debt, notes, instruments or other
      securities (collectively, &#8220;<font style="font-style: italic;">Securities</font>&#8221;) of the Issuer in the open market or otherwise; (ii)&#160;dispose of any or all of its Securities in the open market or otherwise; or (iii)&#160;engage in any hedging or similar
      transactions with respect to the Securities.</div>
    <div><br>
    </div>
    <div id="DSPFPageBreakArea" style="clear: both; margin-top: 12pt; margin-bottom: 12pt;">
      <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-size: 10pt; font-weight: normal; font-style: normal;">3</font></div>
      <div id="DSPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="margin-top: 0.35pt;"><br>
    </div>
    <div style="margin-left: 23pt; font-size: 10pt; font-weight: bold;">Item 5. Interest in Securities of the Issuer</div>
    <div style="margin-top: 0.15pt;"><br>
    </div>
    <div style="margin-left: 36pt; font-size: 10pt;">The Reporting Person has sole voting power and sole dispositive power with regard to 2,645,020 shares of Common Stock, representing approximately 19.99% of the outstanding shares of Common Stock of the
      Issuer as of the date of this Schedule 13D, based upon 13,231,716 shares of Common Stock outstanding as of April 22, 2020, as confirmed in writing by the Issuer, inclusive of 1,322,510 shares of Common Stock held by the Reporting Person as of the
      date of this Schedule 13D and 1,322,510 shares of Common Stock issuable upon exercise of the Warrants held by the Reporting Person.&#160; Except as set forth in Item 4, the Reporting Person did not acquire or sell any shares of Common Stock or other
      securities of the Issuer during the last 60 days.</div>
    <div><br>
    </div>
    <div style="margin-left: 36pt; font-size: 10pt;">As part of the transactions contemplated by the Purchase Agreement, the Reporting Person has entered into voting agreements (collectively, the &#8220;<font style="font-style: italic;">Voting Agreements</font>&#8221;)









      with certain stockholders of the Company (&#8220;<font style="font-style: italic;">Voting Agreement Parties</font>&#8221;), holding approximately 60.6% of the shares of Common Stock outstanding as of the date of this Schedule 13D.&#160; Pursuant to the Voting
      Agreements, the Voting Agreement Parties have agreed, among other things, to vote in support of the transactions contemplated by the Purchase Agreement at a duly convened meeting of stockholders.&#160; As a result of certain provisions contained in the
      Voting Agreements, the Reporting Person may be deemed a to constitute a "group" (within the meaning of Section 13(d)(3) of the Securities Exchange Act) with the Voting Agreement Parties and to have beneficial ownership of the Common Stock
      beneficially owned by the Voting Agreement Parties.&#160; Pursuant to Rule 13d-4 promulgated under the Securities Exchange Act, the Reporting Person disclaims that it constitutes a "group" (within the meaning of Section 13(d)(3) of the Securities Exchange
      Act) with the Voting Agreement Parties and further disclaims any beneficial ownership of any shares of Common Stock beneficially owned by the Voting Agreement Parties. Nothing in this Schedule 13D shall be deemed to constitute an admission by the
      Reporting Person to the contrary.&#160; The Reporting Person paid no funds or other consideration to the Voting Agreement Parties in connection with the execution and delivery of the Voting Agreements.&#160; After the conclusion of the shareholder meeting and
      receipt of the stockholder approval, as contemplated by the Purchase Agreement, to the extent that a &#8220;group&#8221;&#160; between the Reporting Person and the Voting Agreement Parties is deemed to have been constituted, it will be deemed to have been disbanded.</div>
    <div><br>
    </div>
    <div style="margin-left: 36pt; font-size: 10pt;">The form of Voting Agreement is attached as Exhibit 10.2 to the Form 8-K of the Issuer filed with the SEC on April 13, 2020 and is incorporated by reference in this Schedule 13D; any description herein
      of the Voting Agreements is qualified in its entirety by reference to the form Voting Agreement so filed by the Issuer.</div>
    <div style="margin-top: 0.5pt;"><br>
    </div>
    <div style="margin-left: 23pt; margin-top: 0.05pt; font-size: 10pt; font-weight: bold;">Item 6. Contracts, Arrangements, Understandings or Relationships with Respect to Securities of the Issuer</div>
    <div style="margin-top: 0.4pt;"><br>
    </div>
    <div style="margin-left: 36pt; font-size: 10pt;">The information contained above in Item 5 is hereby incorporated by reference into this Item 6.</div>
    <div><br>
    </div>
    <div style="margin-left: 36pt; font-size: 10pt;">The Reporting Person has entered into an Investor Rights Agreement, dated as of April 22, 2020, by and between the Reporting Person and the Issuer (the &#8220;<font style="font-style: italic;">Investor Rights
        Agreement</font>&#8221;), pursuant to which the Reporting Person has been granted the right to designate up to two directors to the board of directors of the Issuer, subject to minimum ownership thresholds. For example, the Investor Rights Agreement
      provides that for so long as the Reporting Person and its affiliates hold at least 15% of the outstanding shares of Common Stock on a fully-diluted basis, the Reporting Person shall have the right to designate two directors to the board of directors
      of the Issuer, and for so long as the Reporting Person and its affiliates hold at least 8% of the outstanding shares of Common Stock on a fully-diluted basis, the Reporting Person shall have the right to designate one director to the board of
      directors of the Issuer, subject to certain qualifications and conditions in the Investor Rights Agreement. <font style="color: #000000;">The Investor Rights Agreement also provides for participation rights for the Reporting Person to participate
        pro rata in future offerings of securities by the Issuer.</font></div>
    <div><br>
    </div>
    <div style="margin-left: 36pt; font-size: 10pt;">The Reporting Person has also entered into a Registration Rights Agreement, dated as of April 22, 2020, by and between the Reporting Person and the Issuer (the &#8220;<font style="font-style: italic;">Registration









        Rights Agreement</font>&#8221;), pursuant to which, among other things, the Issuer is required to prepare and file with the U.S. Securities and Exchange Commission a registration statement with respect to the resale of the securities issued and sold
      pursuant to the Purchase Agreement.</div>
    <div><br>
    </div>
    <div style="margin-left: 36pt; font-size: 10pt;">The Investor Rights Agreement is attached as Exhibit 10.1 to the Form 8-K of the Issuer filed with the SEC on April 22, 2020 and is incorporated by reference in this Schedule 13D; any description herein
      of the Investor Rights Agreement is qualified in its entirety by reference to the Investor Rights Agreement so filed by the Issuer.&#160; The Registration Rights Agreement is attached as Exhibit 4.1 to the Form 8-K of the Issuer filed with the SEC on
      April 22, 2020 and is incorporated by reference in this Schedule 13D; any description herein of the Registration Rights Agreement is qualified in its entirety by reference to the Registration Rights Agreement so filed by the Issuer.</div>
    <div><br>
    </div>
    <div style="margin-left: 36pt; font-size: 10pt;">Except as otherwise described in this Schedule 13D, there are no contracts, arrangements, understandings or relationships (legal or otherwise) between the Reporting Person and any other person with
      respect to any Securities of the Issuer, including but not limited to transfer or voting of any of the Securities, finder&#8217;s fees, joint ventures, loan or option arrangements, puts or calls, guarantees of profits, division of profits or loss, or the
      giving or withholding of proxies.</div>
    <div><br>
    </div>
    <div id="DSPFPageBreakArea" style="clear: both; margin-top: 12pt; margin-bottom: 12pt;">
      <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-size: 10pt; font-weight: normal; font-style: normal;">4</font></div>
      <div id="DSPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="margin-left: 23pt; margin-top: 3.15pt; font-size: 10pt; font-weight: bold;">Item 7. Material to Be Filed as Exhibits</div>
    <div style="margin-top: 0.45pt;"><br>
    </div>
    <div style="margin-left: 36pt; font-size: 10pt;">Exhibit 1 &#8211; Securities Purchase Agreement, dated as of April 12, 2020, by and between Entasis Therapeutics Holdings Inc. and Innoviva, Inc. (incorporated by reference to Exhibit 10.1 to the Form 8-K of
      the Issuer filed with the SEC on April 13, 2020)</div>
    <div style="margin-left: 36pt; font-size: 10pt;">Exhibit 2 &#8211; Form of Warrant (incorporated by reference to Exhibit 4.1 to the Form 8-K of the Issuer filed with the SEC on April 13, 2020)</div>
    <div style="margin-left: 36pt; font-size: 10pt;">Exhibit 3 &#8211; Form of Voting Agreement, between Innoviva, Inc. and the stockholder party thereto (incorporated by reference to Exhibit 10.2 to the Form 8-K of the Issuer filed with the SEC on April 13,
      2020)</div>
    <div style="margin-left: 36pt; font-size: 10pt;">Exhibit 4 &#8211; Investor Rights Agreement, dated as of April 22, 2020, by and between Entasis Therapeutics Holdings Inc. and Innoviva, Inc. (incorporated by reference to Exhibit 10.1 to the Form 8-K of the
      Issuer filed with the SEC on April 22, 2020)</div>
    <div style="margin-left: 36pt; font-size: 10pt;">Exhibit 5 &#8211; Registration Rights Agreement, dated as of April 22, 2020, by and between Entasis Therapeutics Holdings Inc. and Innoviva, Inc. (incorporated by reference to Exhibit 4.1 to the Form 8-K of
      the Issuer filed with the SEC on April 22, 2020)</div>
    <div><br>
    </div>
  </div>
  <div id="DSPFPageBreakArea" style="clear: both; margin-top: 12pt; margin-bottom: 12pt;">
    <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-size: 10pt; font-weight: normal; font-style: normal;">5</font></div>
    <div id="DSPFPageBreak" style="page-break-after: always;">
      <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
  </div>
  <div>
    <div style="text-align: center; margin-left: 23pt; font-size: 10pt; font-weight: bold;">SIGNATURE</div>
    <div style="margin-top: 0.45pt;"><br>
    </div>
    <div style="text-align: justify; text-indent: 36pt; margin-right: 23.6pt; margin-left: 23pt; font-size: 10pt;">After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true,
      complete and correct.</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 36pt; margin-right: 23.6pt; margin-left: 23pt; font-size: 10pt;">Dated: April 23, 2020</div>
    <div><br>
    </div>
    <div><br>
    </div>
    <div style="text-indent: 36pt; margin-right: 23.6pt; margin-left: 23pt;"><font style="font-size: 10pt; font-weight: bold;">INNOVIVA, INC.<br>
      </font><br>
    </div>
    <div>
      <table cellspacing="0" cellpadding="0" border="0" id="z6360a598457d49bbbf0d44cb9b8c469d" style="font-family: 'Times New Roman',Times,serif; font-size: 12pt; width: 100%; border-collapse: collapse; text-align: left; color: rgb(0, 0, 0);">

          <tr>
            <td style="width: 10%; vertical-align: top; font-size: 10pt;" colspan="1">&#160;</td>
            <td style="width: 2%; vertical-align: top;">
              <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">By:</div>
            </td>
            <td style="width: 88%; vertical-align: top;">
              <div style="margin-right: 23.6pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"><u>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;/s/ Geoffrey Hulme&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <br>
                </u></div>
            </td>
          </tr>
          <tr>
            <td style="width: 10%; vertical-align: top; font-size: 10pt;" colspan="1">&#160;</td>
            <td style="width: 2%; vertical-align: top; font-size: 10pt;">&#160;</td>
            <td style="width: 88%; vertical-align: top;">
              <div style="margin-right: 23.6pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Name: Geoffrey Hulme</div>
            </td>
          </tr>
          <tr>
            <td style="width: 10%; vertical-align: top; font-size: 10pt;" colspan="1">&#160;</td>
            <td style="width: 2%; vertical-align: top; font-size: 10pt;">&#160;</td>
            <td style="width: 88%; vertical-align: top;">
              <div style="margin-right: 23.6pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Title: Interim Principal Executive Officer</div>
            </td>
          </tr>

      </table>
    </div>
    <br>
    <div><br>
    </div>
    <div id="DSPFPageBreakArea" style="clear: both; margin-top: 12pt; margin-bottom: 12pt;">
      <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-size: 10pt; font-weight: normal; font-style: normal;">6</font></div>
      <div id="DSPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="text-align: center; font-size: 10pt; font-weight: bold;">SCHEDULE I</div>
    <div><br>
    </div>
    <div style="font-size: 10pt;">The following information is set forth below with respect to each executive officer and director of the Reporting Person: name, business address, position with the Reporting Person and present principal occupation or
      employment and, for persons not employed by the Reporting Persons, the name, principal business and address of any corporation or other organization in which such employment is conducted.</div>
    <div><br>
    </div>
    <table cellspacing="0" cellpadding="0" border="0" id="z98b85b271c5d40589c721f4522e676fa" style="font-family: 'Times New Roman',Times,serif; font-size: 12pt; width: 100%; border-collapse: collapse; text-align: left; color: rgb(0, 0, 0);">

        <tr>
          <td style="width: 20.49%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
            <div style="font-size: 10pt; font-weight: bold;">Name</div>
          </td>
          <td style="width: 17.42%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
            <div style="font-size: 10pt; font-weight: bold;">Business Address</div>
          </td>
          <td style="width: 20.47%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
            <div style="font-size: 10pt; font-weight: bold;">Position with Reporting Person</div>
          </td>
          <td style="margin: 0px 10px 0px 0px; vertical-align: top; width: 21.03%; padding-top: 0px; padding-right: 10px; padding-left: 0px; border-bottom: 2px solid rgb(0, 0, 0);">
            <div style="font-size: 10pt; font-weight: bold;">Present Principal Occupation or Employment</div>
          </td>
          <td style="width: 20.59%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
            <div style="font-size: 10pt; font-weight: bold;">Citizenship</div>
          </td>
        </tr>
        <tr>
          <td style="width: 20.49%; vertical-align: top;">
            <div style="font-size: 10pt; font-weight: bold;"><u>Directors</u></div>
          </td>
          <td style="width: 17.42%; vertical-align: top;">&#160;</td>
          <td style="width: 20.47%; vertical-align: top;">&#160;</td>
          <td style="margin: 0px 10px 0px 0px; vertical-align: top; width: 21.03%; padding: 0px 10px 0px 0px;">&#160;</td>
          <td style="width: 20.59%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 20.49%; vertical-align: top;">
            <div style="font-size: 10pt;">George W. Bickerstaff, III</div>
          </td>
          <td style="width: 17.42%; vertical-align: top;">
            <div style="font-size: 10pt;">(1)</div>
          </td>
          <td style="width: 20.47%; vertical-align: top;">
            <div style="font-size: 10pt;">Director</div>
          </td>
          <td style="margin: 0px 10px 0px 0px; vertical-align: top; width: 21.03%; padding: 0px 10px 0px 0px;">
            <div style="font-size: 10pt;">Managing Director of M.M. Dillon &amp; Co., LLC (2)</div>
          </td>
          <td style="width: 20.59%; vertical-align: top;">
            <div style="font-size: 10pt;">United States</div>
          </td>
        </tr>
        <tr>
          <td style="width: 20.49%; vertical-align: top;">
            <div style="font-size: 10pt;">Mark DiPaolo</div>
          </td>
          <td style="width: 17.42%; vertical-align: top;">
            <div style="font-size: 10pt;">(1)</div>
          </td>
          <td style="width: 20.47%; vertical-align: top;">
            <div style="font-size: 10pt;">Director</div>
          </td>
          <td style="margin: 0px 10px 0px 0px; vertical-align: top; width: 21.03%; padding: 0px 10px 0px 0px;">
            <div style="font-size: 10pt;">Partner and the General Counsel of Sarissa Capital Management LP (3)</div>
          </td>
          <td style="width: 20.59%; vertical-align: top;">
            <div style="font-size: 10pt;">United States</div>
          </td>
        </tr>
        <tr>
          <td style="width: 20.49%; vertical-align: top;">
            <div style="font-size: 10pt;">Jules Haimovitz</div>
          </td>
          <td style="width: 17.42%; vertical-align: top;">
            <div style="font-size: 10pt;">(1)</div>
          </td>
          <td style="width: 20.47%; vertical-align: top;">
            <div style="font-size: 10pt;">Director</div>
          </td>
          <td style="margin: 0px 10px 0px 0px; vertical-align: top; width: 21.03%; padding: 0px 10px 0px 0px;">
            <div style="font-size: 10pt;">President of Haimovitz Consulting, Inc. (4)</div>
          </td>
          <td style="width: 20.59%; vertical-align: top;">
            <div style="font-size: 10pt;">United States</div>
          </td>
        </tr>
        <tr>
          <td style="width: 20.49%; vertical-align: top;">
            <div style="font-size: 10pt;">Odysseas D. Kostas</div>
          </td>
          <td style="width: 17.42%; vertical-align: top;">
            <div style="font-size: 10pt;">(1)</div>
          </td>
          <td style="width: 20.47%; vertical-align: top;">
            <div style="font-size: 10pt;">Director</div>
          </td>
          <td style="margin: 0px 10px 0px 0px; vertical-align: top; width: 21.03%; padding: 0px 10px 0px 0px;">
            <div style="font-size: 10pt;">Partner and Senior Analyst at Sarissa Capital Management LP (3)</div>
          </td>
          <td style="width: 20.59%; vertical-align: top;">
            <div style="font-size: 10pt;">United States</div>
          </td>
        </tr>
        <tr>
          <td style="width: 20.49%; vertical-align: top;">
            <div style="font-size: 10pt;">Sarah Schlesinger</div>
          </td>
          <td style="width: 17.42%; vertical-align: top;">
            <div style="font-size: 10pt;">(1)</div>
          </td>
          <td style="width: 20.47%; vertical-align: top;">
            <div style="font-size: 10pt;">Director</div>
          </td>
          <td style="margin: 0px 10px 0px 0px; vertical-align: top; width: 21.03%; padding: 0px 10px 0px 0px;">
            <div style="font-size: 10pt;">Associate Professor of Clinical Investigation at Rockefeller</div>
            <div style="font-size: 10pt;">University and Senior Attending Physician at Rockefeller University Hospital (5)</div>
          </td>
          <td style="width: 20.59%; vertical-align: top;">
            <div style="font-size: 10pt;">United States</div>
          </td>
        </tr>
        <tr>
          <td style="width: 20.49%; vertical-align: top;">&#160;</td>
          <td style="width: 17.42%; vertical-align: top;">&#160;</td>
          <td style="width: 20.47%; vertical-align: top;">&#160;</td>
          <td style="margin: 0px 10px 0px 0px; vertical-align: top; width: 21.03%; padding: 0px 10px 0px 0px;">&#160;</td>
          <td style="width: 20.59%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 20.49%; vertical-align: top;">
            <div style="font-size: 10pt; font-weight: bold;"><u>Executive Officers</u></div>
          </td>
          <td style="width: 17.42%; vertical-align: top;">&#160;</td>
          <td style="width: 20.47%; vertical-align: top;">&#160;</td>
          <td style="margin: 0px 10px 0px 0px; vertical-align: top; width: 21.03%; padding: 0px 10px 0px 0px;">&#160;</td>
          <td style="width: 20.59%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 20.49%; vertical-align: top;">
            <div style="font-size: 10pt;">Geoffrey Hulme</div>
          </td>
          <td style="width: 17.42%; vertical-align: top;">
            <div style="font-size: 10pt;">(1)</div>
          </td>
          <td style="width: 20.47%; vertical-align: top;">
            <div style="font-size: 10pt;">Interim Principal Executive Officer</div>
          </td>
          <td style="margin: 0px 10px 0px 0px; vertical-align: top; width: 21.03%; padding: 0px 10px 0px 0px;">
            <div style="font-size: 10pt;">Interim Principal Executive Officer of the Reporting Person</div>
          </td>
          <td style="width: 20.59%; vertical-align: top;">
            <div style="font-size: 10pt;">United States</div>
          </td>
        </tr>
        <tr>
          <td style="width: 20.49%; vertical-align: top;">
            <div style="font-size: 10pt;">Marianne Zhen</div>
          </td>
          <td style="width: 17.42%; vertical-align: top;">
            <div style="font-size: 10pt;">(1)</div>
          </td>
          <td style="width: 20.47%; vertical-align: top;">
            <div style="font-size: 10pt;">Chief Accounting Officer</div>
          </td>
          <td style="margin: 0px 10px 0px 0px; vertical-align: top; width: 21.03%; padding: 0px 10px 0px 0px;">
            <div style="font-size: 10pt;">Chief Accounting Officer of the Reporting Person</div>
          </td>
          <td style="width: 20.59%; vertical-align: top;">
            <div style="font-size: 10pt;">United States</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <div style="font-size: 10pt;">(1) 1350 Old Bayshore Highway Suite 400, Burlingame, CA.</div>
    <div style="font-size: 10pt;">(2) M.M. Dillon &amp; Co., LLC is an investment banking firm. The address of M.M. Dillon &amp; Co., LLC is 1 Sound Shore Dr, Greenwich, CT 06830.</div>
    <div style="font-size: 10pt;">(3) Sarissa Capital Management LP is a registered investment advisor. The address of Sarissa Capital Management LP is 660 Steamboat Rd, Greenwich, CT 06830.</div>
    <div style="font-size: 10pt;">(4) Haimovitz Consulting Inc. is a consulting firm. The address of Haimovitz Consulting, Inc. is N/A.</div>
    <div style="font-size: 10pt;">(5) Rockefeller University and the Rockefeller University Hospital are a center for research and graduate education in the biomedical sciences, chemistry, bioinformatics and physics. The address of Rockefeller University
      and Rockefeller University Hospital is 1230 York Ave, New York, NY 10065.</div>
    <div style="font-size: 10pt;"> <br>
    </div>
    <div style="font-size: 10pt;"> <br>
    </div>
  </div>
  <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-size: 10pt; font-weight: normal; font-style: normal;">7</font></div>
</body>
</html>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
